RaySearch Laboratories AB (publ) (FRA:27R)
Germany flag Germany · Delayed Price · Currency is EUR
17.58
0.00 (0.00%)
Last updated: Feb 20, 2026, 9:05 AM CET

RaySearch Laboratories AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1,3441,1921,022843.65641.67
Revenue Growth (YoY)
12.77%16.62%21.16%31.48%-1.52%
Cost of Revenue
101.999.49106.5894.9950.4
Gross Profit
1,2421,093915.58748.66591.28
Selling, General & Admin
650.2576.17558.01481.14422.23
Research & Development
270.4269.38237.74238.77233.44
Other Operating Expenses
29.4-4.52-2.64-1.56-0.35
Operating Expenses
950841.04793.1718.35655.32
Operating Income
292.4251.5122.4830.31-64.04
Interest Expense
-4.5-8.99-9.69-11.48-6.04
Interest & Investment Income
-11.424.91.110.71
Currency Exchange Gain (Loss)
-8.99-7.612.4410.7
Other Non Operating Income (Expenses)
-0.1-0.06-0.01--
Pretax Income
287.8262.87110.0932.38-58.67
Income Tax Expense
6059.3528.528.6-11.36
Net Income
227.8203.5181.5723.78-47.32
Net Income to Common
227.8203.5181.5723.78-47.32
Net Income Growth
11.93%149.49%243.06%--
Shares Outstanding (Basic)
3434343434
Shares Outstanding (Diluted)
3434343434
Shares Change (YoY)
-0.08%----
EPS (Basic)
6.655.942.380.69-1.38
EPS (Diluted)
6.655.942.380.69-1.38
EPS Growth
12.02%149.49%244.84%--
Free Cash Flow
358.9471.97431.64307.26186.19
Free Cash Flow Per Share
10.4813.7712.598.965.43
Dividend Per Share
4.0003.0000.700--
Dividend Growth
33.33%328.57%---
Gross Margin
92.42%91.65%89.57%88.74%92.15%
Operating Margin
21.75%21.10%11.98%3.59%-9.98%
Profit Margin
16.95%17.07%7.98%2.82%-7.37%
Free Cash Flow Margin
26.70%39.59%42.23%36.42%29.02%
EBITDA
397.2286.16214.5269.74-33.24
EBITDA Margin
29.55%24.01%20.99%8.27%-5.18%
D&A For EBITDA
104.834.6692.0539.4330.8
EBIT
292.4251.5122.4830.31-64.04
EBIT Margin
21.75%21.10%11.98%3.59%-9.98%
Effective Tax Rate
20.85%22.58%25.90%26.55%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.